Bladder cancer remains one of the most prevalent urological malignancies worldwide and is frequently associated with high recurrence rates, metastatic progression, and unfavorable long-term clinical outcomes. Although immune checkpoint blockade targeting the PD-1/PD-L1 axis has substantially improved therapeutic management for subsets of patients with advanced bladder cancer, durable clinical responses remain limited because of intrinsic and acquired resistance mechanisms within the tumor microenvironment.
In a recent study published in Genes & Diseases, researchers from Albert Einstein College of Medicine investigated the immunological and therapeutic significance of the immune checkpoint molecule B7x in bladder cancer progression and resistance to PD-1/PD-L1-targeted immunotherapy.
B7x, also recognized as B7-H4, B7S1, or VTCN1, is a potent inhibitory member of the B7/CD28 immunoglobulin superfamily, functioning primarily as a negative regulator of T-cell-mediated immune responses and serves as a critical immune checkpoint in the development and progression of bladder cancer.
Through integrated transcriptomic analyses, immunohistochemical profiling, and functional experimental validation, the study demonstrated that B7x expression is significantly elevated in bladder cancer tissues relative to adjacent normal tissues. Increased B7x expression correlated strongly with advanced tumor stage, aggressive pathological characteristics, and poor overall patient survival, indicating its potential utility as both a prognostic biomarker and a therapeutic target.
Mechanistically, B7x facilitates tumor immune evasion by orchestrating a highly immunosuppressive tumor microenvironment (TME) characterized by the active exclusion of cytolytic antitumor populations, including CD8+ T cells, natural killer (NK) cells, and natural killer T (NKT) cells. Concurrently, B7x promotes the infiltration and local expansion of pro-tumorigenic and immunosuppressive cell types, such as myeloid-derived suppressor cells (MDSCs), M2-polarized macrophages, and regulatory T cells (Tregs).
Experiments with syngeneic mouse models, specifically the immunogenic and "hot" BBN963 cell line, confirm that tumoral B7x expression significantly accelerates tumor growth rates and worsens survival outcomes in immunocompetent hosts. Transcriptomic profiling further highlights that B7x expression is positively correlated with the upregulation of epithelial-mesenchymal transition (EMT) pathways, indicative of heightened metastatic potential and stem-like properties in these cancers.
Clinical data from the IMvigor210 trial further substantiate these findings, revealing that elevated B7x expression is a key determinant of failure in patients undergoing PD-L1 blockade therapy. This correlation suggests that B7x functions as an alternative checkpoint that compensates for PD-1/PD-L1 inhibition, thereby maintaining a state of immune privilege for the tumor.
Importantly, the study evaluated combinatorial immunotherapeutic strategies aimed at overcoming B7x-associated resistance mechanisms. Dual blockade targeting B7x together with PD-1/PD-L1 or CTLA-4 signaling pathways produced substantially enhanced antitumor responses relative to monotherapy approaches. Combination treatment reduced tumor growth, increased infiltration and activation of cytotoxic T cells, diminished immunosuppressive cellular populations within the tumor microenvironment, enhanced production of pro-inflammatory cytokines, and restored effective antitumor immune surveillance. These findings underscore B7x as a high-value, actionable biomarker and a promising therapeutic target for improving clinical outcomes through precision combination immunotherapy.
In conclusion, this study establishes B7x as a central regulator of immune suppression and therapeutic resistance in bladder cancer. The findings provide important mechanistic insight into bladder cancer immune resistance and support the development of combinatorial immune checkpoint blockade strategies incorporating B7x inhibition as a promising therapeutic approach for advanced and treatment-resistant disease.
Reference
Title of the original paper: Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101950
